Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

binimetinib

Aliases
Mektovi, PF-06811462, MEK162
Name
MEKTOVI
INN Name
BINIMETINIB
FDA Approved
Yes

7 clinical trials

1 organization

8 indications

1 document

Indication
Solid Tumor
Indication
Melanoma
Indication
Lung Cancer
Indication
Thyroid Cancer
Indication
Glioma
Indication
Brain Metastases
Indication
Cancer
Indication
Metastatic Melanoma
Clinical trial
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Active (not recruiting), Estimated PCD: 2024-06-18
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS
Status: Recruiting, Estimated PCD: 2027-07-29
Clinical trial
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI-PD-1 THERAPY
Status: Recruiting, Estimated PCD: 2025-05-23
Clinical trial
A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2022-09-22
Clinical trial
A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
Status: Terminated, Estimated PCD: 2022-08-19
Clinical trial
A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
Status: Terminated, Estimated PCD: 2022-01-27
Clinical trial
An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2022-07-11
Document
DailyMed Label: MEKTOVI
Organization
Array BioPharma Inc.